Amy Hamilton leverages a 32-year career at Eli Lilly and Company to help pharmaceutical and life science companies manage and protect their patent portfolios. She co-leads FaegreBD’s pharma/biotech practice for the firm’s health and life sciences industry team.

Amy is driven by a desire to help innovative clients be rewarded for their creativity. She helped spearhead the development of patent law’s written description requirement so that the scope of protection in biotechnology patents appropriately matches the contribution of the inventor. This allows for competition and provides patients with more treatment options while protecting medicines from generic competition.